Dataset Information

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.

ABSTRACT: Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). As riociguat is a relatively new drug, experience of its use in clinical practice is limited, especially in patients who would not have met the inclusion criteria for the pivotal Phase III clinical trials, PATENT-1 and CHEST-1. This article shares our initial practical and clinical experience in switching patients with PAH and CTEPH from the phosphodiesterase type-5 inhibitor sildenafil to riociguat, based on three selected case reports of patients who discontinued sildenafil therapy owing to side effects or disease progression (one patient with idiopathic PAH and two patients with persistent/recurrent CTEPH after PEA). Two cases illustrate our experience with direct switch from sildenafil to riociguat (6-8 h between the last sildenafil dose and the first riociguat dose), and one case illustrates switch to riociguat in a patient who underwent treatment with other PAH-specific therapies between stopping sildenafil and starting riociguat. Symptoms improved with riociguat therapy in two cases; in the third case the patient experienced worsening symptoms 1 month after initiating riociguat and was switched back to sildenafil. These case experiences contribute practical information to assist clinicians in the switch from sildenafil to riociguat therapy in patients with PAH or CTEPH.

SUBMITTER: Andersen A

PROVIDER: S-EPMC5476463 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.

Andersen Asger A Korsholm Kasper K Mellemkjær Søren S Nielsen-Kudsk Jens Erik JE

Respiratory medicine case reports 20170610

Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). As riociguat is a relatively new drug, experience of its use in clinical practice is limited, especially in patients who would not have met the inclusion criteria for the pivotal Phase III clinical tri ...[more]

PMID: 28652963

Similar Datasets

Project description:Background:Anti-IgE (omalizumab) and anti-IL5/IL5R (reslizumab, mepolizumab and benralizumab) treatments are available for severe allergic and eosinophilic asthma. In these patients, studies have shown beneficial effects in oral corticosteroid use and exacerbations. The aim of this retrospective single-center study was to evaluate the effect of biological therapy on severe asthma and to compare different therapies. Methods:We collected and analysed results of anti-IL5/IL5R and anti-IgE therapies for asthma from January 2009 until October 2019 in specialized care. We compared number of exacerbations, asthma symptoms and use of per oral corticosteroids and antimicrobics because of asthma before and during biological therapy, and in a separate analysis need for per oral corticosteroids, antimicrobics or surgery due to upper respiratory tract diseases in asthmatics receiving biologicals. The analyses were done using the Chi square test, T-test or Mann-Whitney U -test, the Kruskall-Wallis test or the Wilcoxon test. Results:Of 64 patients, 40 used continuous per oral corticosteroid therapy prior to biological therapy. The mean daily dose of per oral corticosteroid was reduced in those with anti-IL5/IL5R therapy (-?3.0?mg, p?=?0.02). The number of annual per oral corticosteroid courses decreased in both the anti-IL5/IL5R (-?2.8 courses, p?<?0.05) and anti-IgE groups (-?1.3 courses, p?<?0.05). The number of annual antibiotic courses (-?0.7 courses, p?=?0.04) and total number of exacerbation events (-?4.4 events/year, p?<?0.05) were reduced in the anti-IL5/IL5R group. In the 55 asthma patients analysed for upper respiratory tract findings, the results suggested a reduction in need for chronic rhinosinusitis surgery during biological therapy. Conclusions:Results with biological therapies in this real-life clinical setting are comparable to those reported in clinical trials. Biological therapy reduces exacerbations and per oral corticosteroid use. Trial registration:NCT04158050, retrospectively registered 6.11.2019.

Project description:BACKGROUND:Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. METHODS:A total of 41 consecutive patients with severe, persistent allergic, eosinophilic asthma, uncontrolled despite treatment with omalizumab, were enrolled in seven certified Clinical Respiratory Units of Southern Italy (Catania, Catanzaro, Foggia, Bari, Palermo, and two University Respiratory Units of Naples) and shifted to mepolizumab without a wash-out period. Data at baseline, after at least 12?months of therapy with omalizumab, and after at least 12?months of treatment with mepolizumab were collected. RESULTS:After at least 12?months of therapy with mepolizumab, patients experienced a significant decrease in the number of exacerbations/year (5.8?±?1.8 versus 0.7?±?0.9, p?<?0.0001), an increment of asthma control test score (12?±?2.7 versus 21.9?±?2.7, p?<?0.0001), an increase in pre-bronchodilator forced expiratory volume in 1?s (1.56?±?0.45?l versus 1.86?±?0.52?l, p?<?0.0001), and a reduction of blood eosinophils (584?±?196 cells/µl versus 82?±?56 cells/µl, p?<?0.0001). The percentage of patients who were dependent on corticosteroids significantly decreased from 46% at baseline to 5% during treatment with mepolizumab. CONCLUSION:Results of our real-life multicentric experience confirms that the shift to mepolizumab could be a good therapeutic strategy in severe eosinophilic allergic asthma not previously controlled by omalizumab. The reviews of this paper are available via the supplemental material section.

Dataset Information

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.

Publications

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets